Department of Medical Oncology, Hacettepe University Oncology Hospital, Ankara, Turkey.
Department of Medical Oncology, Istinye University, Istanbul, Turkey.
Biomark Med. 2021 Sep;15(13):1123-1130. doi: 10.2217/bmm-2020-0674. Epub 2021 Aug 16.
Blood-based biomarkers like prognostic nutritional index (PNI) are readily available biomarkers for immunotherapy efficacy, although the data are limited. So, we aimed to evaluate the association between PNI and overall survival (OS) in immunotherapy-treated patients. For this retrospective cohort study, data of 150 immunotherapy-treated advanced cancer patients were evaluated. The association between clinical factors and OS was evaluated with multivariate Cox-regression analyses. After a median follow-up of 8.5 months, 94 patients died. The median OS was 11.07 months. The low PNI (hazard ratio [HR]: 2.065; p = 0.001), high lactate dehydrogenase (HR: 2.515; p = 0.001) and poor Eastern Cooperative Oncology Group (ECOG) status (HR: 2.164; p = 0.009) was associated with poorer OS in multivariate analyses. In our experience, survival with immunotherapy was impaired in patients with lower PNI and higher lactate dehydrogenase levels and poorer ECOG status.
基于血液的生物标志物，如预后营养指数（PNI），是免疫治疗疗效的常用生物标志物，尽管数据有限。因此，我们旨在评估 PNI 与免疫治疗患者的总生存期（OS）之间的关联。 这项回顾性队列研究评估了 150 名接受免疫治疗的晚期癌症患者的数据。使用多变量 Cox 回归分析评估了临床因素与 OS 之间的关联。 在中位随访 8.5 个月后，94 名患者死亡。中位 OS 为 11.07 个月。低 PNI（风险比 [HR]：2.065；p = 0.001）、高乳酸脱氢酶（HR：2.515；p = 0.001）和较差的东部合作肿瘤学组（ECOG）状态（HR：2.164；p = 0.009）与多变量分析中的较差 OS 相关。 根据我们的经验，PNI 较低、乳酸脱氢酶水平较高和 ECOG 状态较差的患者的免疫治疗生存率受损。
